38860 Federal Register / Vol. 65, No. 121 / Thursday, June 22, 2000 / Notices

DEA has considered the factors in title

21, United States Code, section 823(a)

and determined that the registration of

Chirex Technology Center, Inc., DBA

Chirex Cauldron to manufacture

amphetamine is consistent with the

public interest at this time. DEA has

investigated the firm to ensure that the

company’s registration is consistent

with the public interest. The

investigation included inspection and

testing of the company’s physical

security systems, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: June 7, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–15688 Filed 6–21–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on March 30, 2000, Radian

International LLC, 14050 Summit Drive

#121, P.O. Box 201088, Austin, Texas

78720–1088, made application by

renewal to the Drug Enforcement

Administration to be registered as an

importer of the basic classes of

controlled substances listed below:

Drug Schedule

Cathinone (1235) .......................... I

Drug Schedule

Methcathinone (1237) .................. I

N-Ethylamphetamine (1475) ........ I

gamma hydroxybutyric acid

(2010).

I

Ibogaine (7260) ............................ I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) .......................... I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine (7400).I

3,4-Methylenedioxy-N-ethylamphetamine (7404).I

3,4-Methylenedioxymethamphetamine (7405).I

4-Methoxyamphetamine (7411) ... I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Ethorphine (except HC1) (9056) .. I

Heroin (9200) ............................... I

Pholcodine (9314) ........................ I

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Meperidine (9230) ........................ II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

levo-alphacetylmethadol (9648) ... II

Oxymorphone (9652) ................... II

The firm plans to import small

quantities of the listed controlled

substances for the manufacture of

analytical reference standards.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than July 24, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import basic classes of

any controlled substances in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: June 8, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–15687 Filed 6–21–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of title

21 of the Code of Federal Regulations

(CFR), this is notice that on December

10, 1999, Salsbury Chemicals, Inc., 1205

11th Street, Charles City, Iowa 50616–

3466, made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

amphetamine (1100) and by letter dated

March 14, 2000, for registration to bulk

manufacture methylphenidate (1724),

basic classes of controlled substances

listed in Schedule II.

The firm plans to manufacture

amphetamine and methylphenidate for

distribution as bulk product.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substance

may file comments or objections to the

issuance of the proposed registration.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than August

21, 2000.